Looks like you’re on the UK site. Choose another location to see content specific to your location
Bristol-Myers Squibb announces immunotherapy collaboration with Apexigen
Bristol-Myers Squibb has announced that it is embarking on a new collaboration with Apexigen for a new lung cancer immunotherapy trial.
Apixegen's immuno-oncology drug APX005M will be trialled alongside Bristol-Myers Squibb's Opdivo, which is designed to target solid tumours, even in more aggressive forms of the disease, such as non-small-cell lung cancer.
APX005M is designed to reverse the suppression of the immune system that is an unfortunate side effect of many current cancer treatments, while Opdivo is an immune checkpoint inhibitor – the first drug of its kind to receive regulatory approval back in July 2014. Since then, it has been granted approval in 57 countries.
Combining these drugs may have benefits for different forms of cancer, but it is just lung cancer that will be focused on in this new trial for now.
Fouad Namouni, head of the oncology development at Bristol-Myers Squibb, commented: "Targeting the tumour microenvironment through activation of antigen-presenting cells is a novel approach that we are excited to add to our immuno-oncology strategy."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
Image: ClPhotos via iStock
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard